Table 2. Clinical outcomes of critically-ill patients grouped by premorbid angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage (n = 952).
| Non-users (n = 476) | ACEi/ARB users (n = 476) | p value | |
| Occurrence & severity of AKI | |||
| AKI (total cases) | 318 (66.8) | 335 (70.4) | 0.264 |
| AKI, stage 2-3 | 233 (48.9) | 252 (52.9) | 0.420 |
| Timing of AKI | |||
| AKI before ICU admission | 176 (37.0) | 203 (42.6) | 0.085 |
| AKI at ICU admission | 9 (1.9) | 16 (3.4) | 0.223 |
| AKI after ICU admission | 133 (27.9) | 116 (24.4) | 0.238 |
| Events in the follow-up period | |||
| Length of ICU stay, days | 5.0 (2.0-11.0) | 5.0 (2.0-10.0) | 0.129 |
| Length of hospitalization, days | 18.5 (9.0-34.0) | 17.0 (7.5-37.5) | 0.685 |
| In-hospital mortality | 143 (30.0) | 121 (25.4) | 0.128 |
| eGFR at hospital discharge | 50.5 (28.0-76.0) | 48.9 (29.7-70.1) | 0.420 |
| Dialysis at hospital discharge | 23 (4.8) | 21 (4.4) | 0.761 |
| Mortality within 1 year | 177 (37.2) | 152 (31.9) | 0.102 |
| Mortality or dialysis within 1 year | 199 (41.8) | 165 (34.7) | 0.028 |
ACEi, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; ICU, intensive care unit.